Skip to main content
VRPXOTCdelisted

Virpax Pharmaceuticals, Inc.

Biopharma developer (SEC filing verified)·Pre-clinical·Berwyn, PA, United States·CEO: Mr. Jatinder Dhaliwal
OncologyNeurologyInfectious DiseasePainMusculoskeletal

VRPX evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for VRPX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

2.9/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

$14K

Cash Runway

1.6 mo

Lead Asset

anqlar (Preclinical)

Next Catalyst

Financial data as of Dec 31, 2024.

Tracking 5 pipeline candidates for Virpax Pharmaceuticals, Inc..

Run Virpax Pharmaceuticals, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Virpax Pharmaceuticals, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway0.4

1.6 months

Financial Health0.5

OCF -$3M · Net income -$3M

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Pipeline

Financials

Short Interest

as of May 22, 2026
% of float
1.8%
Days to cover
0.0
Shares short
23,082
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

VRPX short interest

Governance

Frequently asked questions

What is Virpax Pharmaceuticals, Inc.'s lead drug candidate?

Virpax Pharmaceuticals, Inc.'s most advanced tracked candidate is anqlar (Preclinical) for prophylactic viral barrier to inhibit viral infection by influenza or SARS-CoV-2.

Who is the CEO of Virpax Pharmaceuticals, Inc.?

Mr. Jatinder Dhaliwal is the chief executive officer of Virpax Pharmaceuticals, Inc. (VRPX).

Where is Virpax Pharmaceuticals, Inc. headquartered?

Virpax Pharmaceuticals, Inc. (VRPX) is headquartered in Berwyn, PA, United States.

What therapeutic areas does Virpax Pharmaceuticals, Inc. focus on?

Virpax Pharmaceuticals, Inc. develops therapies across Oncology, Neurology, Infectious Disease, Pain, Musculoskeletal.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.